Adamo, Daniela (2024) Vortioxetine versus SSRI/SNRI with pregabalin augmentation in treatment-resistant Burning Mouth Syndrome: a prospective clinical trial. [Tesi di dottorato]
![[thumbnail of Tesi_Adamo.pdf]](https://www.fedoa.unina.it/style/images/fileicons/other.png "Tesi_Adamo.pdf") |
Documento PDF
Tesi_Adamo.pdf Visibile a [TBR] Amministratori dell'archivio Download (1MB) | Richiedi una copia |
| Tipologia del documento: | Tesi di dottorato |
|---|---|
| Lingua: | English |
| Titolo: | Vortioxetine versus SSRI/SNRI with pregabalin augmentation in treatment-resistant Burning Mouth Syndrome: a prospective clinical trial |
| Autori: | Autore Email Adamo, Daniela daniela.adamo@unina.it |
| Data: | 2024 |
| Numero di pagine: | 89 |
| Istituzione: | Università degli Studi di Napoli Federico II |
| Dipartimento: | Neuroscienze e Scienze Riproduttive ed Odontostomatologiche |
| Dottorato: | Medicina clinica e sperimentale |
| Ciclo di dottorato: | 37 |
| Coordinatore del Corso di dottorato: | nome email Francesco, Beguinot beguino@unina.it |
| Tutor: | nome email Mignogna, Michele Davide [non definito] |
| Data: | 2024 |
| Numero di pagine: | 89 |
| Parole chiave: | burning mouth syndrome, vortioxetine, pregabalin, pain, anxiety, depression |
| Settori scientifico-disciplinari del MIUR: | Area 06 - Scienze mediche > MED/28 - Malattie odontostomatologiche |
| Informazioni aggiuntive: | Appartengo al ciclo 37° |
| Depositato il: | 17 Ott 2025 14:41 |
| Ultima modifica: | 09 Ago 2026 05:55 |
| URI: | https://www.fedoa.unina.it/id/eprint/16304 |
Abstract
Objectives: The treatment of Burning Mouth Syndrome (BMS) represents a challenge in tailoring appropriate medication for individual patients. The augmentation with pregabalin to conventional treatment has shown promising outcomes in relieving pain and improving the quality of life in chronic pain conditions. This study aimed to compare the efficacy of vortioxetine with other antidepressants (SSRIs/SNRIs) in combination with pregabalin in a cohort of unresponsive BMS patients and to predict treatment response by using clinical data. Methods: A 52-week randomized, open-label, comparative clinical study was conducted, enrolling 203 BMS patients previously treated with one antidepressant for 12 weeks and non-responders to the treatment (clinical trial registration: NCT06025474). The study sample included two groups: Group A (136) received vortioxetine, while Group B (67) received SSRIs/SNRIs. Pregabalin (75mg/day) was added to both groups, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks. Treatment response was assessed with VAS and SF-MPQ, HAM-A and HAM-D scores at 12, 24, 36 and 52 weeks. Stepwise logistic regression analysis was used to predict treatment response. Results: 84 (61.8%) BMS patients in Group A and 39 (58.2%) in Group B showed treatment response. Group A reported a faster onset of action compared to Group B (44.8% versus 22.4% at time 1; p:0.002**) and lower adverse event rates (8.8% versus 20.8%; p:0.001). Conclusions: The addition of pregabalin to vortioxetine may be considered a potential treatment option for BMS. Further research is required to corroborate these findings and optimize personalized treatment approaches for BMS patients.
Downloads
Downloads per month over past year
Actions (login required)
 |
Modifica documento |
